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Recent  work  from  this  laboratory  (1,  2)  has  demonstrated  that  mouse  resident 
peritoneal  macrophages  release  the  slow-reacting substance  (SRS), 1 leukotriene  C 
[5(S)-hydroxy-6(R)-glutathionyl-7,9,11,14-eicosatetraenoic acid; LTC]  in response to 
a  phagocytic stimulus. No data are as yet available concerning leukotriene synthesis 
by other mouse macrophage populations. It is of particular interest to know whether 
pulmonary  macrophages  are  also  able  to  produce  large  quantities  of leukotrienes 
because of the sensitivity of the peripheral airways of the lung to SRS  (3, 4).  In this 
report, we present the results of studies of zymosan-induced leukotriene synthesis by 
mouse pulmonary alveolar macrophages, obtained by bronchoalveolar lavage and by 
pulmonary interstitial macrophages, isolated by enzymatic digestion of lung tissue. 
Materials and Methods 
Pulmonary  Macrophage  Cultures.  Pulmonary  alveolar macrophages  (PAM)  and  pulmonary 
tissue macrophages (PTM) were obtained from male and female ICR mice weighing 25-30 g 
(Trudeau Institute Inc., Saranac Lake, NY)  by a  modification of the method of Bluss~ Van 
Oud Alblas and Van Furth (5). Each mouse was anesthetized with an intraperitoneal injection 
of 5 mg of sodium pentobarbital (Abbott Laboratories, North Chicago, IL). The chest cavity 
was opened, and the aorta and inferior vena cava were cut. Blood was removed from the lungs 
by perfusion with calcium- and magnesium-free phosphate-buffered saline containing 1 mM 
EDTA,  which  was  injected  into  the  right  ventricle of the  heart  until  the  lung  tissue was 
uniformly white. The trachea was then cannulated, and the lungs were washed five times with 
1 ml of buffered saline containing EDTA at 37°C. These washes, which contained PAM, were 
combined and placed on ice. For culture, the cells were washed once with buffered saline and 
resuspended at a  cell density of 1 ×  106/ml in minimum essential alpha medium (e~-MEM; 
Gibco Laboratories, Grand Island Biological Co., Grand Island, NY) containing 10% fetal calf 
serum. The cell suspensions were then added to 60-mm Diam plastic tissue culture dishes (3 
ml), 15-mm culture wells (0.3 ml), or 12-mm glass cover slips (0.1 ml). After 2 h of incubation 
at 37°C in 95% air/5% CO2, the cultures were washed vigorously to remove nonadherent cells 
and overlaid with fresh a-MEM containing 10% serum. Cultures contained 2.5  zt: 0.1  ×  105 
adherent cells/60-mm dish. 
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Institutes of Health, and a grant in aid from the Squibb Institute for Medical Research. 
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PTM were isolated from the lung tissue after completion of lavage. The heart and lungs 
were removed en bloc; the heart, trachea, bronchi, and hilar connective tissue were carefully 
dissected away. PTM were obtained by mincing the lungs with scissors and  incubating the 
resulting fragments for 60 min at 37°C in Krebs-Ringer phosphate buffer supplemented with 
5.4 mM glucose (KRPG) containing trypsin (200 U/ml), collagenase (18 U/ml), and DNAse 
(140 U/ml). All enzymes were from Worthington Biochemical Corp., Freehold, NJ. The tissue 
was  filtered through  sterile gauze,  and  the  cells were  washed  twice  with  KRPG.  Culture 
conditions were the same as for PAM except that initial cell suspensions contained  1 ×  l0  7 
cells/ml of medium. Approximately 2.2 :l: 0.2 ×  106 adherent cells/60-mm dish were recovered. 
In the case of PTM or PAM cultures to be maintained for longer than 24 h, the washed 
monolayers were treated with trypsin (50  U/ml in a-MEM)  at 37°C  for 20 min  to remove 
contaminating fibroblasts. The cells were then washed again with buffered saline and overlaid 
with fresh a-MEM containing 10% serum. 
Characterization of Macrophage Populations.  Macrophages cultured on  glass coverslips were 
stained for peroxidase by the method of Kaplow (6) and for nonspecific esterase by the method 
of Li  et  al.  (7).  The  phagocytosis of zymosan  was  quantitated  by  direct  phase  contrast 
microscopy of cells fixed in 2.5% glutaraldehyde following a 60 min exposure to zymosan. Cell 
viability was assessed by trypan blue exclusion, and cells remained >95% viable throughout all 
of the experimental procedures. 
Release of Arachidonic Acid (20:4)  Metabolites by Macrophage Cultures.  For the study of 20:4 
release and  metabolism, macrophages were  incubated  for  12  h  in a-MEM containing  10% 
serum  and  0.5  pCi/ml  of [5,6,8,9,11,12,14,15-SH]20:4  (sp  act  78  Ci/mmol;  New  England 
Nuclear,  Boston,  MA).  Unless  otherwise  stated,  cells were  labeled  immediately after  the 
adherence purification step. After the labeling period, the cells were washed three times with 
buffered saline and placed in serum-free a-MEM containing 160 #g/ml of unopsonized zymosan 
(ICN K  & K  Laboratories, Inc., Plainview, NY) prepared by the method of Bonney et ai. (8). 
The cells were then cultured for the designated time periods at 37°C in 95% air/5% CO2 to 
permit the release of 20:4 metabolites into the culture medium. 
Studies of the time course of total 20:4 release by PTM used cells cultured in 15-mm wells. 
At the end of the culture period with zymosan, the medium was removed and placed in glass 
scintillation vials for radioactivity measurements.  Cell monolayers were  washed  twice  and 
scraped from the wells into 0.3 ml of a solution of 0.05% Triton X-100 (Rohm and Haas Co., 
Philadelphia, PA). The wells were scraped again with 0.3 ml of the Triton solution, and the 
radiolabel content of the cell lysates was determined. 
For the  characterization of 20:4  metabolites released by  macrophages,  [aH]20:4-1abeled 
cultures of PAM or PTM  in 60-mm dishes were used. Aliquots (50 pl) of the medium were 
taken initially for radioactivity measurements, and the cells were then incubated for 4 h in the 
presence or absence of zymosan. After aliquots were again removed to determine radiolabel 
content, the medium was placed on ice. The cells were washed and scraped into 0.05%  Triton 
X-100 (2 ×  0.75 ml). Portions (100 #1) of the lysates were assayed for radiolabel content, and 
protein was determined by the method of Lowry et al. (9). 
The 20:4 metabolites in the culture medium were extracted by the method of Unger et al. 
(10).  Briefly, to 1 ml of medium was added 1 ml ethanol and  10 #1 88%  (wt/wt) formic acid, 
and the resultant solutions were extracted twice with  1 ml of chloroform containing 0.005% 
(wt/vol) butylated hydroxytoluene (BHT;  Sigma Chemical Co., St. Louis, MO). The lower 
(chloroform) phases were combined, evaporated to dryness under nitrogen, and dissolved in the 
appropriate starting solvent  for  further  purification by reversed-phase high-pressure liquid 
chromatography (HPLC). A column of 5 # Ultra.sphere ODS, 4.6 mm ×  25 cm (Altex, Rainin 
Instruments,  Woburn,  MA)  eluted  at  a  flow  rate  of  1  ml/min  was  used  for  all  HPLC 
purifications. Two separate solvent systems were used. System 1  : the first solvent was 60 ml of 
methanol/water/acetic acid  (65:34.9:0.1,  vol/vol/vol) adjusted  to  pH  5.4  with  ammonium 
hydroxide, followed by 40 ml of methanol/acetic acid (100:0.01,  vol/vol). System 2:  elution 
was with  120  ml of water:acetonitrile/benzene/aeetic acid (76.7:23:0.2:0.1,  vol/vol/vol/vol) 
followed by 40 ml of methanol/acetic acid (100:0.01,  voi/vol). Fractions of 1 ml were collected, 
and the radiolabel content of whole fractions or aliquots was determined. The elution charac- 
teristics  of  prostaglandins  (PG),  leukotrienes,  monohydroxyeicosatetraenoic acids  (mono- 722  MACROPHAGE ARACHIDONIC ACID METABOLISM 
HETEs), and unreacted 20:4 were determined by the use of pure radiolabeled standards (see 
below).  Those  of  di-HETEs  and  12-L-hydroxy-5,8,10-heptadecatrienoic acid  (HHT)  were 
elucidated by comparison with the corresponding 20:4 metabolites produced by polymorpho- 
nuclear leukocytes (11) and platelets (12), respectively.  In addition, the elution of these di- 
HETEs from the reversed phase HPLC column using methanol/water/acetic acid (75:25:0.01, 
vol/vol/vol) as the solvent was identical to that reported by others (9-19 min [11]). Except in 
the case of LTC, all 20:4 metabolites were identified on the basis of their HPLC elution time. 
Purification of Leukotrienes.  Chemically pure samples of teukotrienes for ultraviolet or amino 
acid analysis were obtained from the medium of cells that had been labeled with [3H]20:4 and 
exposed to zymosan for 4 h. The 20:4 metabolites were extracted from the medium as described 
above, and the extracts were concentrated under nitrogen. The concentrated extract from ~4 
ml of medium was applied in a total volume of 100 #1 of 80% ethanol to a column (0.6 ×  10 
cm)  of activated  silicic  acid  (Silicar CC-7;  Mallinckrodt Inc.,  St.  Louis,  MO)  packed  in 
chloroform (2). 
The columns were eluted sequentially with 5  ml of chloroform, 35  ml of 20%  (vol/vol) 
methanol in chloroform and 20 ml of methanol, all containing 0.005% BHT. The methanol 
eluates containing the leukotrienes were combined, concentrated under reduced pressure,  and 
rechromatographed  as  above on a  single silicic  acid column, with  BHT omitted from  the 
eluting solvents.  The  methanol eluate  from  this  column was  concentrated under reduced 
pressure and subjected to HPLC using system 1. 
Amino Acid Analysis of LTC.  Fractions from HPLC  containing purified LTC were  dried 
under reduced pressure and hydrolyzed in evacuated ampoules in 6 M HC1 for 20 h at  110°C. 
Amino acid  analysis was  performed  on  a  Durrum  D-500  automatic amino acid  analyzer 
(Dionex Corp. Sunnyvale, CA) by previously described methods (13, 14) using norleucine as an 
internal standard. 
Bioassay of LTC.  The bioassay for SRS activity was performed using an isolated guinea pig 
ileum in Tyrode's solution in the presence of atropine (1 #M) and pyrilamine maleate (1/zM), 
by the method of Chakravarty (15). One unit of SRS activity was defined as  that amount 
producing a contraction equal to that elicited by 5 ng of histamine. 
Macrophage Lipid Extraction, Separation, and Analysis.  Macrophages prelabeled for  12 h with 
[3H]20:4 were washed, placed in a-MEM with or without zymosan (160 #g/ml), and incubated 
for 4 h. Aliquots of the medium were taken for radioactivity measurements before and after the 
4  h  incubation. The cells  were  washed  and scraped  into 0.9% saline, and cell lipids were 
extracted by the procedure of Bligh and Dyer (16). Concentrated lipid extracts were applied to 
0.4-g columns of activated silicic  acid  (Silicar CC-4;  Mallinckrodt Inc.). Neutral lipids and 
phospholipids were sequentially eluted with 10 ml each of chloroform and methanol, respec- 
tively (17). Fatty acid methyl esters  of phospholipids were prepared by transesterification in 
methanolic HC1 and analyzed by gas-liquid chromatography on 1/8-in X 10-ft columns of 10% 
SP-2330  on  100/200 Chromosorb WA/W (Supelco,  Inc., Bellefonte, PA)  at  180°C with a 
carrier gas flow rate of 30 ml/min (17). 
To  determine the  localization of  [3H]20:4  in  individual cell  phospholipids,  extracts  of 
radiolabeled PTM that had not been exposed  to zymosan were subjected to two-dimensional 
thin-layer chromatography on plates of silica gel (Redi-Coat plates, Supelco, Inc.). To facilitate 
the visualization of lipid on the plates, phospholipid (0.1/~mol) extracted from unlabeled  J774 
cells (a macrophage-like cell line) was added to the samples. Plates were developed in the first 
dimension with chloroform/methanol/ammonium  hydroxide (65:35:5, vol/vol/vol) and in the 
second dimension with chloroform/acetone/acetic acid/methanol/water (30:40:10:10:5, vol/ 
vol/vol/vol/vol) (18). The lipid-containing  regions were  visualized by exposing the plates to 
iodine vapors,  and  the  silica  gel  was  scraped  from  the  plates  into  scintillation vials  for 
radioactivity determinations. 
Macrophage phospholipid phosphorus content was determined on cell lipid extracts by the 
method of Ames and Dublin (19). 
Assay of "y-Glutamyl Transpeptidase Activity.  Assay solutions contained 0.5  M  Tris HCI  (pH 
8.5),  25 mM glycylglycine, and 2.5  mM L-),-glutamyl-p-nitroanilide  (Sigma Chemical Co.). 
Macrophages cultured in a 60-mm dish were washed twice with buffered saline and overlaid 
with 1 ml of the reaction solution. After incubation for 6 h at 37°C with gentle agitation, 0.5 ROUZER  ET AL.  723 
ml of the solution was removed and combined with 0.25 ml ice-cold 15% (wt/vol) trichloroacetic 
acid. The solutions were placed on ice for 15 min, and protein was removed by centrifugation. 
The optical density was measured at 410 nm after neutralization with solid sodium bicarbonate 
(20).  One  unit  of 7-glutamyl transpeptidase activity is defined as  1 pmol of p-nitroaniline 
produced per hour at 37°C. 
Radioactivity Measurements.  The  radiolabel  content  of samples  was  measured  by  liquid 
scintillation counting in Hydrofluor (National Diagnostics, Inc., Somerville, N  J) using an LKB 
Ultrobeta 1210 scintillation counter (LKB Instruments, Inc., Rockville, MD). Corrections were 
made for counting efficiency (---40% for all). 
Radiolabeled Standards of 20:4 Metabolites.  The  recovery of 20:4  metabolites through  ex- 
traction and purification procedures and their elution times on HPLC were monitored with 
the  aid  of  radiolabeled  standards.  [5,8,9,11,12,14,15-aH]6-ketoPGFt~  (80-120  Ci/mmol), 
[5,6,8,9,11,12,14,15-SH]thromboxane  B2  (TXB2,  100-150  Ci/mmol),  [9-aH]PGF2,  (5-15  Ci/ 
mmol), and [5,6,8,11,12,14,15-SH]  PGE2 (100-200 Ci/mmol) were purchased from New England 
Nuclear.  [all] 12-hydroxy-5,8,10,14-eicosatetraenoic  acid  (12-HETE)  and  [aH]5-hydroxy- 
6,8,11,14-eicosatetraenoic  acid  (5-.I--IETE) were  obtained  from  calcium  ionophore A23187- 
stimulated human blood platelets (12)  and polymorphonuclear leukocytes (21),  respectively, 
and were the generous gift of Dr. Nicholas Pawlowski of The Rockefeller University. [aH]LTC 
was obtained from [aH]20:4-1abeled mouse peritoneal macrophages (1). [SH]leukotriene D [5(S)- 
hydroxy-6(R)-cysteinylglycyl-7,9,11,14-eicosatetraenoic  acid; LTD]  was derived from the in- 
cubation of [SH]LTC with 7-glutamyltranspeptidase (22).  [aH]Leukotriene E  [5(S)-hydroxy- 
6(R)-e~steinyl-7,9,11,14-eicosatetraenoie  acid; LTE] was similarly obtained as a reaction prod- 
uct of [ H]LTD with leueine aminopeptidase (22). All leukotrienes were purified by silicic acid 
column chromatography and HPLC as described above. Standards were dissolved in a-MEM 
from cultures of unlabeled macrophages challenged with zymosan for extraction and HPLC 
purification. 
Results 
Mouse  Pulmonary Macrophage Populations.  Two  macrophage  populations  were  ob- 
tained  from  lungs  on  the  basis of their  accessibility to  lavage.  PAM  were  readily 
obtained by washing the tracheo-bronchial tree five times with saline, whereas PTM 
included those cells remaining in the alveoli after the lavage in addition to interstitial 
macrophages. The cytochemical and phagocytic properties of the two cell populations 
as well as cell recoveries are summarized in Table I. These data indicate that typical 
macrophages comprised at least 80 and 95% of PTM  and PAM populations, respec- 
tively. 
Uptake of [aH]20:4 by Pulmonary Macrophages and Its Distribution in Cell Lipid.  During 
12 h of exposure to [3H]20:4, the uptake of the radiolabel by PAM and PTM  cultures 
was  similar (82  :!=  16%  for PAM  and  74  4"  21%  for PTM).  Two-dimensional  thin- 
TABLE I 
Characteristics of Mouse Pulmona(y Macrophage Populations* 
Percent 
Cells/mouse  #g cell  Percent  Zymo-  Percent  peroxi- 
Cell type  (X 10-5)$  protein/  phago-  san/  esterase  dase 
10  6 cells  cytic§  cell[[  positive  positive 
PAM  1.6 + 0.4  114  96  9  99  1 
PTM  3.8 ± 0.4  92  81  8  80  9 
* Assays were carried out on purified cell populations after 12 h of incubation. 
:]: The number of adherent cells recovered per mouse. 
§ The percent of the total number of cells ingesting zymosan during 1 h of 
exposure to a maximal dose of 160 #g/ml. 
[I The average number of zymosan particles ingested per cell. MACROPHAGE  ARACHIDONIC ACID  METABOLISM  724 
layer chromatography of PTM  lipid  extracts indicated  that  ~40%  of the  aH  was 
localized in phosphatidylcholine, whereas phosphatidylethanolamine, phosphatidyli- 
nositol, and phosphatidylserine contained 23, 16, and 7%, respectively. The remaining 
14% was recovered from neutral lipid. Less than  1% of the cell-associated radiolabel 
was present as the free fatty acid. 
Release of [~H]20:4 by Pulmonary Macrophages in Response to Zymosan.  When [aH]20:4- 
labeled  cultures of PTM  or PAM  were challenged  with  a  phagocytic stimulus  of 
unopsonized zymosan, they released aH selectively from their phospholipid pool, and 
this radiolabel was recovered in the culture medium. After 4 h of exposure to 160/xg/ 
ml of zymosan, a dose that elicited a maximal response, PTM and PAM released 13.7 
:t: 5.1% and 5.5 :t: 1.9% of their phospholipid [all]20:4, respectively. In contrast, cells 
not challenged with zymosan released 2.9 +_ 1.1% of the radiolabel in their phospho- 
lipid pool over a 4-h period. 
Fig.  1 shows  the time course of the release of [aH]20:4 from PTM phospholipid 
after the  cells were challenged with  zymosan  (160/lg/ml).  An  initial  burst  of aH 
release that  lasted for 30-60 min after the addition of zymosan was  followed by a 
slower rate of release which continued for up to 4 h. Because culture of macrophages 
in serum-free medium for longer than 4 h after the addition of zymosan was associated 
with a loss in cell viability, later time points were not evaluated. 
The effect of culture  time on  [aH]20:4 release  by pulmonary macrophages  was 
examined in parallel cultures of PTM and PAM incubated for 12 or 60 h before the 
zymosan challenge. The results indicated  that  increased culture time resulted in a 
decrease in [nH]20:4 release in response to zymosan. PTM cultured for 60 h released 
6.0  +  0.5%  of their phospholipid  [~H]20:4  during  a  4-h  exposure to  zymosan,  in 
24- 
"O 
20 
"0  "~. 
C 
1  2  3  4 
Time (h) 
Flo.  1.  Time course of 20:4 release by zymosan-challenged PTM. Triplicate cultures of [*H]20:4- 
labeled  PTM  in  15-mm wells  were incubated  for the  designated  times in ot-MEM  with  ((2)) or 
without (A)  160/*g/ml unopsonized zymosan. The medium and cells  were harvested as described 
in  Materials  and  Methods.  Their  radiolabel  content  was  determined.  The  percent  release  of 
phospholipid 20:4 at time t was calculated from the formula: 
(Mr-  Mo) 
percent release =  ×  100, 
(Ct +  Mt -  Mo)0.86 
where Mt -  dpm in the medium at time t; Mo =  dpm in the medium at time t  -  0; Cc -- dpm in 
the ceils at time t; and 0.86 corrects for the percent of total [SH]20:4 incorporated into phospholipid. 
Data presented are the mean :1: range of values from two separate experiments. ROUZER El" AL.  725 
contrast to 13.2 +  1.1% [aH]20:4 release by 12-h PTM cultures. Corresponding values 
for PAM phospholipid [all]20:4 release were 2.5 +  0.4% by 60-h cultures and 4.8 + 
0.5% by 12-h cultures. The decrease in 20:4 release was not the result of cell loss or 
death, and 60-h PTM and PAM cultures phagocytized zymosan to an extent equal 
to that of 12-h cultures. In contrast, no effect of culture time was seen in 20:4 released 
in  response  to  10 /~g/ml  calcium  ionophore A  23187.  Thus,  12-h  PTM  cultures 
released 11.4% of their phospholipid fatty acid 20:4 after ionophore challenge, whereas 
60-h cultures released 10.0%. PAM cultured for 12 and 60 h released 9.2% and  10.3% 
of their 20:4, respectively, in response to the ionophore. 
Synthesis  of L TC by PTM and PAM.  Initial  studies  of the  radiolabeled products 
released by [aH]20:4-1abeled PTM indicated that LTC was a major 20:4 metabolite 
of these cells.  This metabolite was subsequently purified from PTM culture medium 
by extraction, silicic acid column chromatography, and  HPLC  (Fig. 2).  A  peak of 
radioactivity was obtained from HPLC, which co-migrated with LTC isolated from 
mouse peritoneal macrophages (elution time =  19 min). The ultraviolet spectrum of 
this material (Fig. 2) indicated an absorption maximum at 280 nm with shoulders at 
270 nm and 292 nm, confirming the presence of a conjugated triene structure. Amino 
acid analysis yielded 0.82 nmol of glutamic acid and 1.0 nmol of glycine per nanomole 
of leukotriene as determined by absorbance at 280 nm (¢ =  40,000 [23]). Other amino 
acids, including cysteine, were recovered at <0.1  nmol/nmol leukotriene. This result 
was consistent with the structure of LTC, but not of LTD or LTE. The failure to 
quantitatively recover cysteine in acid hydrolysates of leukotrienes has been reported 
by  others  (23).  Bioassay  of the  20:4  metabolite  in  a  standard  guinea  pig  ileum 
preparation (Fig. 2) indicated a bioactivity of ~2 U  of SRS activity per picomole of 
LTC. 
Approximately 3.2 nmol of LTC (based on the absorbance at 280 nm) was isolated 
from PTM cultures totaling 3.7 mg protein (4.1  X  10  ~ cells). The recovery of both 
LTC and LTD through the extraction and purification procedure was ~25%. Thus, 
PTM produced 3.4 pmol of LTC//Ig cell protein. No LTD was obtained. 
Leukotriene synthesis was also studied in parallel PAM cultures. As in the case of 
PTM, LTC was the major ieukotriene synthesized by PAM; however, small quantities 
of two other 3H-labeled metabolites were isolated from PAM culture medium. These 
have been tentatively identified as LTD and LTE on the basis of co-migration with 
radiolabeled  standards  on  HPLC  (Fig.  2).  Because of the  small  numbers  of cells 
available and the relatively low release of [all]20:4 in response to zymosan, insufficient 
quantities of the leukotrienes were obtained from PAM cultures to allow spectral or 
amino acid analyses. 
y-Glutamyl  Transpeptidase Activity in PTM and PAM Cultures.  The enzyme ~,-glutamyl 
transpeptidase catalyzes the conversion of LTC to LTD (22). Assay of this enzyme in 
12-h cultures of PTM and PAM indicated low levels of activity (37 U//~g cell protein 
in PAM and 13 U/~g cell protein in PTM), in comparison with other cell types such 
as  lymphoid cell lines  (50-1,000  U/~g  cell protein  [24])  or human  blood platelets 
(2,100 U/~g cell protein [20]). Culture of PTM for 60 h did not result in a significant 
change  in  enzymatic activity  (18  U//~g cell protein).  The low levels of enzymatic 
activity in pulmonary macrophage cultures correlates well with the synthesis of LTC 
as the major leukotriene metabolite. 
Total 20:4 Metabolites ofPTMand PAM.  We next examined total 20:4 metabolites 726  MACROPHAGE  ARACHIDONIC ACID METABOLISM 
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FtG.  2.  aH elution profiles from final HPLC purification of leukotrienes produced by [SH]20:4- 
labeled PTM  (  ) and PAM (---) challenged with zymosan. Leukotrienes released into the 
culture medium were extracted and purified by silicic acid column chromatography followed by 
HPLC system 1. Relevant elution times are: LTC, 19-20 min; LTD, 34-35 min; LTE, 46-47 min. 
Top:  ultraviolet spectrum of LTC  isolated from PTM culture  medium. Bottom: response of a 
standard guinea pig ileum preparation to LTC purified from PTM culture medium. The first arrow 
indicates sample addition, and the second arrow indicates washout. 
synthesized  by zymosan-challenged  PTM  and  PAM  using  HPLC  system  1,  which 
allows  the mutual  separation  of cyclo-oxygenase and lipoxygenase products.  A  rep- 
resentative chromatogram for PTM cultures is shown in Fig. 3. In profiles from both 
PTM and PAM cultures, LTC was evident as a prominent peak of radiolabel (elution 
time =  19 min) together with significant quantities of cyclo-oxygenase products that 
constitute  the  major  radiolabeled  species  in  the  peak  eluting  at  4-15  min.  Minor 
amounts  of HETEs  and  unreacted  20:4 were  also evident,  as  were,  in  the  case  of 
PAM, small peaks of LTD (35 min) and LTE (46 min).  Separation of the individual 
cyclo-oxygenase products formed by pulmonary macrophages using HPLC system 2 
indicated  that both PAM and PTM  formed TXA2 (isolated as TXB2)  and PGE~. In 
addition,  PTM, but  not  PAM, synthesized  low levels of prostacyclin  (isolated  as 6- 14 
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FK;.  3.  HPLC chromatogram of 20:4 metabolites released by [3H]20:4-1abeled PTM. Cells were 
incubated for 4 h with (~)  or without (- -  -) 160 #g/ml zymosan. 20:4 metabolites in the medium 
were extracted and subjected to HPLC using system 1. The elution times for relevant standards are: 
PG and TXB2, 4-15 min; LTC, 19-20 min; di-HETEs, 20-50 min; HHT, 57-58 rain; mono-HETEs 
and unreacted 20:4, 70-90 min. The recovery of 20:4 metabolites through the extraction and HPLC 
was 70-75%. 
keto-PGFla) (Fig. 4). The specific release of all 20:4 metabolites was calculated from 
radiolabel data and is expressed in Table II as percent of total 20:4 release obtained 
after zymosan treatment. It is evident that lipoxygenase products (LTC and HETEs) 
represent the major portion of the identified 20:4 metabolites of these cells. 
Alterations in PTM Phospholipids with Phagocytosis.  Direct fatty acid analysis indi- 
cated that the phagocytosis of zymosan was associated with a  15% reduction in the 
20:4 content of PTM  phospholipid  (Table III). This value was  in  good agreement 
with the specific release (zymozan-treated cultures -  control cultures) of aH from the 
cells,  which  indicated  a  loss  of  14%  of the  phosphofipid' radiolabel.  In  a  second 
experiment, values for specific release of phospholipid 20:4 were 10% from fatty acid 
analysis and 12% from radiolabel data. 
PTM cultures contained 302 :t  18 pmol of phospholipid/#g cell protein, a  value 
that did not change with phagocytosis (295 :t: 5 pmol/gg cell protein). Therefore, the 
20:4 content of PTM was  140 pmol/gg cell protein, and a specific release of 11% of 
phospholipid [SH]20:4 represented a loss of 15 pmol of 20:4/#g cell protein. 
Discussion 
In  these  studies,  we  have  examined  20:4  metabolism  in  two  mouse  pulmonary 
macrophage populations. These include PAM, which were obtained by lavage of the 
airways,  and  PTM,  which  were  isolated  by enzymatic digestion.  Of the  two  cell 
populations, PTM released greater quantities (two- to threefold) of 20:4 metabolites 
than did PAM under identical culture conditions. Because the PTM cultures were 
undoubtedly a mixture of interstitial and alveolar macrophages of unknown propor- 
tions,  it  is  possible  that  the capacity of the  pulmonary interstitial  macrophage  to 728  MACROPHAGE  ARACHIDONIC ACID METABOLISM 
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F[o.  4.  HPLO  chromatogram {system 2)  of cyclo-oxygenase products  released by PTM.  Top: 
elution profile of tri.tiated PC, and TX standards.  Bottom: elution profile of extracts of culture 
medium from [aH]20i4-1abeled PTM cultures incubated for 4 h in the presence (  ) or absence 
(- - -) of zymosan (160 lag/ml). Recovery of the 20:4 metabolites was 65-70%. 
release 20:4 metabolites is actually greater than indicated by the data for PTM. The 
differences  in  20:4 release  observed  between  PTM  and  PAM  populations  did  not 
appear to result from the use of proteolytic enzymes to isolate PTM, because exposure 
of PAM  to these  enzymes did  not  alter  the zymosan-induced 20:4 release  by those 
cells.  Recent studies  by Bluss~ Van Oud Alblas and Van  Furth  (5)  have suggested 
that alveolar macrophages originate as pulmonary interstitial  macrophages which, in 
turn, are derived from blood monoeytes. Once in the alveolar space, the macrophages 
are continually exposed to foreign particulate matter and are very actively phagocytic. 
It is possible  that  this  constant  stimulation  of macrophages in the alveoli results  in 
changes in the cells that are accompanied by a  down regulation of 20:4 metabolism 
as observed in PAM cultures. 
The release  of 20:4 in  response  to zymosan decreased  with  culture  time  in  both 
PTM  and  PAM  populations.  Treatment  of 60-h  PTM  cultures  with  the  proteoly- 
tic enzymes used for their isolation failed to restore 20:4 release to levels observed in 
12-h cultures, which indicates that these changes were not an artifact of the isolation 
procedure.  Furthermore,  time  in  culture  did  not  affect  20:4 release  in  response  to 
calcium ionophore A23187. It has been suggested that unopsonized zymosan interacts ROUZER  ET  AL.  729 
TASLE  II 
20:4 Metabolites Synthesized by PAM and PTM in Response to Zymosan* 
20:4 Metabolite  PTM  PAM 
Prostacyclin  5-7  -- 
TXA2  6-10  7-12 
PGE2  10-15  10-15 
HETES +  20:4  9-12  14-18 
di-HETEs  20-25  20-25 
LTC  20-25  10-15 
LTD  --  1-2 
LTE  --  1-2 
Unidentified:~  10-30  20-30 
* Values are  expressed  as  the percent  of total 20:4 specifically released in 
response  to  zymosan  and  were  calculated  as  follows:  20:4  metabolite as 
Met, -  Mete X  100% 
percent of total 20:4 =  M, -  Mc  , where Met,  --  dpm of the 
metabolite recovered from zymosan treated cultures;  Mete -- dpm of the 
metabolite  recovered  from  parallel  control  cultures;  M,  --  dpm  in  the 
medium from zymosan treated cultures; and M, =  dpm in the medium from 
parallel control cultures. 
af Unidentified products consisted primarily of radiolabel co-migrating with 
cyclo-oxygenase products in HPLC system 1, but not in system 2. 
TAnLE  III 
Effect of Phagocytosis on PTM Phospholipid Fatty Acid Composition* 
Fatty acid 
Mole percent of fatty acid 
Control  Zymosan  A 
14:0  8.1 3= 0.3:~  8.0 3= 0.3  -0.1 
16:0  29.0 3= 1.3  31.6 3= 1.0  +2.0 
18:0  18.7 3= 0.6  20.3 3= 0.2  +1.6 
18:1  14.1 ±  0.4  15.4 3= 0.3  +1.3 
18:2  6.7 3= 1.5  5.0 3= 0.9  -1.7 
20:4  23.4 ±  0.3  19.8 3= 1.1  -3.6 
* Cultures of PTM  were  incubated for 4  h  in the presence or absence of 
unopsonized zymosan (160 #g/ml). The cells were then washed and scraped 
into isotonic saline. The fatty acid content of isolated phospholipids was 
determined by gas-liquid chromatography after transesterification. 
:~ Each value is the mean 3= SD of four chromatographic analyses of a single 
sample. 
with  the  macrophage  membrane  by  binding  to  the  receptor  for  mannose-terminal 
glycoproteins (25). Preliminary  studies also indicated that 20:4 metabolism  stimulated 
by opsonized  zymosan  and  immune  complex-coated  Sephadex  beads  decreases with 
time. These observations suggest that an alteration in receptor-mediated  20:4 metab- 
olism occurs in cultured  pulmonary  macrophages. 
Spectroscopic  quantitation  of purified  [aH]LTC  obtained  from radiolabeled  PTM 
cultures indicated that its specific activity (69 dpm/pmol  LTC)  was in good agreement 
with that of the total cell phospholipid  20:4  (70 dpm/pmol  20:4).  Furthermore,  fatty 
acid  analysis  indicated  that  the  release  of 3H  from  cell  phospholipid  provided  an 
accurate measurement  of the 20:4 released by the cells in response to zymosan. Similar 
results  were  obtained  in  [3H]20:4-1abeled  mouse  resident  peritoneal  macrophages, 730  MACROPHAGE ARACHIDONIC ACID METABOLISM 
which were also shown  to release  [aH]PGE2  having a  specific activity equivalent  to 
that of the total phospholipid 20:4 pool (1, 26). These considerations indicate that the 
specific activity of the [aH]20:4 in macrophage phospholipids may be used to calculate 
molar quantities of isolated 20:4 metabolites from their radiolabel content.  In Table 
IV are the results of such calculations for the 20:4 metabolites of PTM. Also included 
are corresponding values for resident peritoneal macrophages cultured under similar 
conditions,  providing  a  direct  comparison  of  two  macrophage  populations  from 
distinct body sites in a  single species. Both PTM  and peritoneal macrophages are rich 
sources of 20:4 metabolites; however,  there are differences in the proportions of the 
released 20:4 that is metabolized by the cyclo-oxygenase and lipoxygenase pathways. 
Lipoxygenase products predominate in PTM  20:4 metabolites and LTC is the single 
major compound.  In contrast, peritoneal macrophages secrete relatively more cyclo- 
oxygenase products, with PGE~ predominating. 
The  finding that  pulmonary  macrophages  are rich sources of LTC  suggests that 
these cells may play a  role in inflammatory or immunologic reactions that  result in 
SRS  formation  in  the lung. Considerable work in  the past has shown  that  specific 
antigen challenge of IgE-sensitized lung tissue results in significant SRS production; 
however, studies of purified pulmonary mast cells have indicated that these cells are 
not capable of releasing large quantities of leukotrienes (27, 28). The possibility must 
therefore  be  considered  that  the  macrophage  is  the  source  of SRS  in  these  IgE- 
mediated reactions. The present studies demonstrate LTC production in response to 
phagocytic stimuli, and, at present, macrophage 20:4 metabolism in response to IgE 
TABLE IV 
20:4 Metabolites Synthesized by Mouse Resident Peritoneal and Pulmonary 
Macrophage Populations* 
Peritoneal  20:4 Metabolite  PTM  macrophages 
Prostacyclin  5.5  - 7.2  0.7-1.1 
TXA2  --  0.9-1.5 
PGE2  15-20  1.5-2.3 
HETEs + 20:4  2.1-4.6  4.3-5.6 
LTC  3.5-7.0  3.0-3.8 
Unidentified  --  1.5-4.5 
Values given are picomoles of 20:4 metabolite per microgram of cell protein 
specifically released in response to a maximal zymosan stimulus. PTM were 
cultured for 4 h and peritoneal macrophages for 2 h after zymosan addition. 
Total release of 20:4 metabolites  was  calculated by  the  formula:  pmol 
Met  A 
metabolite//~g protein  (M + C -  Mo)P X ~, where Met =  dpm of iso- 
lated metabolite  recovered from HPLC;  M  =  dpm of medium  after the 
incubation with or without zymosan; C = dpm of ceUs after the incubation 
with or without zymosan; Mo -- dpm in the medium before the incubation 
with  or without  zymosan;  R  =  the recovery of the metabolite through 
extraction and HPLC;  P =  the fraction of total 20:4 incorporated  into cell 
phospholipid  (0.70 for peritoneal macrophages and 0.86 for PTM);  and A 
=  the phospholipid  20:4 content  (86 pmol//~g cell protein  for peritoneal 
macrophages, 140 pmol//.tg cell protein for PTM). 
The specific release of 20:4 metabolites is defined as the release by zymosan 
treated cultures minus the release by control cultures. The specific release of 
total 20:4 metabolites by peritoneal  macrophages and PTM was approxi- 
mately 35 pmol/~tg cell protein and 15 pmol/btg cell protein, respectively. ROUZER ET AL.  731 
and antigen has not been reported. However, the binding of IgE to the macrophage 
membrane  as  well  as  cell-cell  interactions  between  mast  ceils  and  mononuclear 
phagocytes have been suggested as possible mechanisms for the stimulation of LTC 
release by macrophages (28, 29). 
The synthesis of LTC by pulmonary macrophages in response to phagocytic stimuli 
raises other questions concerning the possible involvement of SRS generation during 
acute and chronic inflammatory states. The recently reported vascular effects of LTC 
and LTD suggest that these substances are potent proinflammatory agents (30). Thus, 
it is likely that  the role of SRS formation in the lung is not  limited to immediate 
hypersensitivity reactions. 
Summary 
Mouse resident pulmonary macrophages were subdivided into alveolar (PAM) and 
interstitial (PTM) populations on the basis of accessibility to pulmonary lavage, and 
zymosan-induced arachidonic acid (20:4) metabolism was examined in both popula- 
tions  labeled  with  [3H]20:4.  Maximal  phagocytic  doses  of unopsonized  zymosan 
induced the specific release of 11% of phospholipid 20:4 by PTM and 4.6% by PAM. 
Direct fatty acid analysis of [3H]20:4-1abeled PTM cultured in the presence or absence 
of zymosan indicated that  the specific activity of the  [ZH]20:4  in cell phospholipid 
provided an accurate measure of 20:4 released by the cells, and could therefore be 
used to quantitate the synthesis of 20:4 metabolites by PTM in vitro. The single major 
20:4 metabolite of PTM was the slow-reacting substance leukotriene C, which was 
synthesized in quantities of 3-4 pmol//~g cell protein (280-370 pmol/10  ~ cells), and 
comprised  20-25%  of the  released  20:4.  PTM  also  synthesized  prostaglandin  Ez, 
prostacyclin, thromboxane A2, and hydroxyeicosatetraenoic acids. In contrast, PAM 
produced  leukotrienes  D  and  E  in  addition  to  leukotriene  C,  prostaglandin  E2, 
thromboxane A2, and hydroxyeicosatetraenoic acids. Prostacyclin formation by PAM 
was not observed. These studies define a set of experimental conditions for the study 
of 20:4 metabolism by pulmonary macrophages, and demonstrate that these cells are 
rich sources of LTC as well as other 20:4 oxygenated products. 
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